TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03069664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: endoscopic retrograde cholangiopancreatography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered Self-expandable Metal Stent
Description: Pancreatic duct stent
Study: NCT04706377

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B12 fix 1000mcg
Description: oral dispersible tablet with vitamin B12 1000mcg
Study: NCT00923611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fimasartan
Study: NCT04276376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w
Study: NCT04706377

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT04276376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID
Study: NCT03193827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line filtration
Description: In-line filtration is used during anesthesia and postoperative 96 hrs in study group to purify endovascular fluids administrations reducing postoperative phlebitis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients are treated with standard intravenous solutions and vascular access management
Study: NCT02874703

Intervention type: OTHER
Intervention: Cardiac MRI/MRS

Intervention type: OTHER
Intervention: Cardiac MRI/MRS
Study: NCT02067676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Description: The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Description: The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Description: The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Description: The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Description: The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Description: The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alhydrogel®, aluminum hydroxide adjuvant (alum)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alhydrogel®, aluminum hydroxide adjuvant (alum)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alhydrogel®, aluminum hydroxide adjuvant (alum)
Study: NCT03746119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette vapor containing nicotine
Description: A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed e-solution containing nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette vapor, nicotine free
Description: A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed nicotine free e-solution.
Study: NCT03159039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged slow exhalation technique
Description: Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
Study: NCT03276091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colofit+ intervention
Description: Personnalized phone call, done by the medical student in the name of Adémas-69, organized cancers screening in the Rhône area association. This is a motivational call to encourage patients with an immunochemical fecal test positive, to realized their colonoscopy.
Study: NCT04153552

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HLNatural, Inc. Upset Stomach Relief
Description: Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
Study: NCT01553370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Increased Dairy Intake
Description: 3 additional servings of low fat dairy will be consumed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased Dairy Intake
Description: 3 additional servings of low fat dairy will be consumed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental carbohydrate
Description: Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
Study: NCT00720109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Some patients undergo cranial RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02189135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
Study: NCT01553370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental carbohydrate
Description: Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
Study: NCT02313961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Description: Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
Study: NCT04162860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eso-SPONGE® device
Description: Preemptive ENP therapy will be carried out with either an Eso-SPONGE® device system (Eso-SPONGE®, B. Braun Melsungen AG, Melsungen, Germany). Eso-SPONGE® consists of an open-pored polyurethane foam fitted to a gastric tube. Secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg.
Study: NCT03595553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Description: ridinilazole (200 mg bid)
Study: NCT02181725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Rehabilitation Program
Description: The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
Study: NCT02895867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full fat dairy
Description: Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
Study: NCT03595553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: vancomycin (125 mg qid)
Study: NCT02238444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin
Description: From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin
Description: From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study: NCT00782769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutinyn Vaginal Ring 4mg
Study: NCT02895867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat dairy
Description: Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
Study: NCT04165421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention group
Description: Education and Family conversations
Study: NCT03186352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photoactivated disinfection
Description: After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying
Study: NCT00324961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil tablets
Description: adefovir dipivoxil once daily 10 mg orally
Study: NCT03899467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT0918
Description: anti-tumor activity
Study: NCT00542308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Individual dose titration weekly i.v. doses
Study: NCT01386866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of \[14C\]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
Study: NCT03181256

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of sputum

Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Undergo collection of nasal epithelium

Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Undergo collection of buccal epithelium

Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Undergo collection of urine

Intervention type: PROCEDURE
Intervention: Pulmonary Function Test
Description: Undergo pulmonary function test

Intervention type: PROCEDURE
Intervention: Computed Tomography (CT)
Description: Undergo chest CT

Intervention type: OTHER
Intervention: Laboratory Biomarker
Description: Correlative studies
Study: NCT00782769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutinyn Vaginal Ring 6mg
Study: NCT03954535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free2b
Description: The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-Placebo
Description: Access to the website with entertainment features and resources - but no session content.
Study: NCT01440621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyridoxine
Description: Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
Study: NCT00903175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
Study: NCT03028454

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger Root
Description: Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing rice flour powder.
Study: NCT00968513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: (N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Treatment
Description: (N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
Study: NCT02640508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Will be taken orally at 20-24 mg daily in each 21 day cycle.
Study: NCT03506893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alphapump
Description: Alfapump® device: a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder where they are eliminated by the urinary tract.~Medical device marked CE, used in the indication provided for marking
Study: NCT00085735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given orally
Study: NCT03506893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ascites puncture
Description: Hospitalizations for evacuating ascites are performed at least twice a month and can be up to 2 times a week. A clinical and biological examination is carried out at each visit.
Study: NCT00223080

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV vCP1521 + AIDSVAX
Description: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC Placebo + AIDSVAX Placebo
Description: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection
Study: NCT04343235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: five day course of furosemide 20mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: labetalol
Description: 200mg labetalol BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: labetalol
Description: 200mg labetalol BID
Study: NCT03237286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Description: Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous ketamine
Description: Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Cognitive Training
Description: Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer-based Cognitive Training
Description: Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression.
Study: NCT01763996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat placebo
Description: Febuxostat placebo-matching capsules
Study: NCT00903175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
Study: NCT03826732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help based on ACT
Description: ACT-based self-help book and regular support by trained facilitators
Study: NCT00661115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
Study: NCT01763996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat placebo
Description: Febuxostat placebo-matching capsules
Study: NCT03057925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Ultrasound-guided Percutaneous Microwave Ablation